Leuprolide Acetate For Depot Suspension

Introduction Overview

Generic Name

leuprolide acetate for depot suspension

Brand Name

Lupron Depot

Dosage Form

Injection for intramuscular use

Drug Class

Gonadotropin releasing hormones; Hormones / antineoplastics

Pharmacokinetics

Absorption:
Lupron Depot is administered as an intramuscular injection in a depot formulation, utilizing microspheres that allow for sustained release of leuprolide acetate over an extended period ranging from 1 to 6 months, depending on the dosage. Upon injection, the drug is absorbed slowly from the muscle tissue into the systemic circulation, providing a prolonged pharmacologic effect without the need for frequent dosing. The depot formulation ensures a relatively steady plasma concentration of leuprolide acetate over the dosing interval, thereby maintaining continuous suppression of gonadotropin secretion. Absorption can be influenced by the site of injection and muscle vascularization, but the depot microsphere technology minimizes variability.

Distribution:
Leuprolide acetate distributes extensively in the body following absorption. It is a synthetic peptide with moderate plasma protein binding, though exact binding percentages are not well specified, typical for peptides. The drug crosses the blood-brain barrier to exert its effects at the pituitary level. Distribution volume is consistent with extracellular fluid volume, reflecting limited penetration into adipose tissue. In pediatric populations and those with altered body composition, distribution may vary but does not require dose adjustment based solely on pharmacokinetics.

Metabolism:
Leuprolide is primarily metabolized enzymatically by peptidases to smaller peptide fragments and amino acids, which are inactive and readily eliminated. The metabolism occurs mainly in peripheral tissues and the blood. No significant involvement of hepatic cytochrome P450 enzymes has been reported, reducing concerns about hepatic drug-drug interactions. The metabolic process leads to a gradual decrease in circulating active drug, correlating with the controlled release from the depot formulation.

Elimination:
The inactive metabolites are predominantly eliminated via renal excretion. The elimination half-life after depot administration is prolonged due to the sustained-release mechanism, with plasma levels sufficient for pharmacological effect over several weeks to months depending on the formulation. Renal impairment is not expected to substantially affect elimination due to the peptide nature and depot delivery system, though clinical data remain limited. Regular dosing intervals ensure maintenance of therapeutic levels before complete elimination.

Dosage Forms

Available Dosage Forms:
Lupron Depot is supplied as an intramuscular injection suspension formulated in microspheres for prolonged release. Specific dosage strengths and their administration intervals are:
- Lupron Depot (adult formulations): 3.75 mg (1-month), 7.5 mg (1-month), 22.5 mg (3-month), 30 mg (4-month), 45 mg (6-month)
- Lupron Depot-Ped (pediatric formulations): 7.5 mg, 11.25 mg, 15 mg (1-month); 11.25 mg, 30 mg (3-month); 45 mg (6-month)

Dosages for Adults and Adolescents:
- Advanced Prostate Cancer: 7.5 mg monthly, or extended intervals with 22.5 mg every 3 months, 30 mg every 4 months, or 45 mg every 6 months.
- Endometriosis: 3.75 mg IM monthly for up to 6 months, alone or with 5 mg daily norethindrone acetate add-back to mitigate hypoestrogenic side effects; retreatment with add-back therapy limited to 6 months.
- Uterine Fibroids: 3.75 mg IM monthly for up to 3 months to reduce bleeding and anemia; treatment duration limited; symptoms recur after discontinuation.

Specific Patient Populations:
- Central Precocious Puberty (CPP) in children aged 1 year and older (Lupron Depot-Ped): Dosage individualized by body weight.
- ≤25 kg: 7.5 mg monthly
- >25 kg to ≤37.5 kg: 11.25 mg monthly
- >37.5 kg: 15 mg monthly
- Extended dosing options: 3-month or 6-month injectables for pediatric use (11.25 mg or 30 mg for 3 months; 45 mg for 6 months), dosing adjusted according to clinical response and weight changes.
- Injection is given intramuscularly into upper arm, thigh, or buttock muscles.
- Patients with renal or hepatic impairment do not require dose adjustment, but clinical monitoring advised.

Product excipients vary by dosage to provide controlled release and stability, including polylactic acid copolymers, mannitol, carboxymethylcellulose sodium, polysorbate 80, purified gelatin, and acetic acid to maintain pH and suspension integrity.

Mechanism Of Action

Lupron Depot contains leuprolide acetate, a synthetic analog of gonadotropin-releasing hormone (GnRH) agonist. Upon initial administration, leuprolide stimulates the GnRH receptors in the anterior pituitary gland, resulting in a transient surge in the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Consequently, this causes a temporary increase in the production of gonadal steroids such as testosterone in men and estrogen in women.

With continuous administration, leuprolide causes desensitization and downregulation of pituitary GnRH receptors. This receptor downregulation leads to a marked reduction in LH and FSH secretion, effectively producing a profound hypo-gonadotropic state. As a result, there is a significant decrease in circulating sex hormone levels (testosterone and estrogen), which achieves a state analogous to surgical castration, often referred to as “chemical castration”. The suppression of sex steroid hormones reduces hormone-dependent pathologies.

At the cellular level, leuprolide binds with high affinity to GnRH receptors, inducing receptor internalization and decreased receptor mRNA expression over time. This results in impaired synthesis and release of gonadotropins. The induced hypogonadism interrupts the hormonal stimulation of target tissues, such as prostate gland in men, endometrial tissue in women, and gonadal tissue in puberty, thereby controlling diseases like prostate cancer, endometriosis, uterine fibroids, and precocious puberty.

Clinically, this mechanism underpins leuprolide's role in managing hormone-dependent conditions. Compared to GnRH antagonists like degarelix that immediately block receptor activation, leuprolide’s initial hormone flare may necessitate additional antiandrogen therapy in prostate cancer to manage symptom exacerbation. Its long-acting depot formulations improve patient compliance by providing sustained drug release, maintaining hormone suppression over weeks to months. Extensive clinical studies have validated its efficacy and safety profile in diverse indications.

Pharmacological Actions

GnRH agonist causing initial stimulation followed by downregulation of pituitary GnRH receptors
Suppression of LH and FSH secretion leading to decreased gonadal steroid production
Induction of reversible hypogonadism or chemical castration
Reduction of testosterone levels in advanced prostate cancer treatment
Inhibition of estrogen production to manage endometriosis and uterine fibroids
Suppression of premature puberty onset in central precocious puberty via hormonal control
Use as a hormonal adjunct in assisted reproductive technology (IVF) to control ovulation timing
Sustained-release depot formulation allowing prolonged pharmacologic effect with reduced dosing frequency
Decreased sex hormone stimulation leading to atrophy of hormone-dependent tissues
Modulation of pituitary-gonadal axis to achieve therapeutic goals
Alteration of neuroendocrine feedback loops involved in reproductive hormone regulation
Decreased bone resorption associated with sex steroid deficiency may occur with prolonged use

Therapeutic Or Clinical Uses

Treatment of advanced prostate cancer by suppressing testosterone production
Management of endometriosis-associated pain and reduction of endometriotic lesions
Reduction of uterine leiomyomata (fibroids) symptoms and improvement in anemia due to bleeding
Treatment of central precocious puberty (CPP) in children aged 1 year and older to delay early puberty signs
Use as part of assisted reproduction protocols to prevent premature ovulation
Adjunct treatment combined with norethindrone acetate add-back therapy to mitigate hypoestrogenic side effects in endometriosis
Palliative treatment to improve quality of life in hormone-dependent cancers
Temporary chemical castration as an alternative to surgical orchiectomy
Control of hormone-dependent uterine bleeding
Management of hormone-responsive gynecological conditions requiring short-term hormonal suppression
Reduction of pain and bleeding in fibroid patients who are iron deficient
Suppression of gonadotropin levels in pediatric patients to limit premature sexual maturation

Side Or Adverse Effects

Injection site reactions including pain, swelling, redness, and abscess formation
Hot flashes and excessive sweating (vasomotor symptoms)
Generalized pain and musculoskeletal complaints such as joint pain
Gastrointestinal disturbances including nausea and vomiting
Edema and fluid retention causing swelling
Respiratory symptoms such as dyspnea
Urinary difficulties and impotence
Testicular atrophy and decreased sperm production in males
Fatigue, weakness, and decreased energy levels
Headache, migraine, dizziness, and mood swings
Vaginal inflammation, discharge, and itching in females
Weight changes including gain or loss
Depression, emotional lability, irritability, and other psychiatric symptoms
Serious allergic reactions including anaphylaxis
Rare but potentially fatal Stevens-Johnson syndrome/toxic epidermal necrolysis
Temporary symptom flare including tumor flare in prostate cancer and increased puberty signs in CPP
Increased risk of cardiovascular events such as myocardial infarction and stroke
QT/QTc interval prolongation risking cardiac arrhythmias
Increased intracranial pressure with symptoms of pseudotumor cerebri
Potential development of diabetes, hyperglycemia, and metabolic syndrome
Bone density loss and risk of osteoporosis with prolonged hypoestrogenism or hypotestosteronism

Precautions

Careful monitoring for initial symptom flare especially in prostate cancer requiring possible antiandrogen therapy
Avoid use in patients with known hypersensitivity to leuprolide or similar GnRH analogs
Regular cardiovascular monitoring due to increased risk of heart disease and stroke
Monitoring of bone density in patients on prolonged therapy to prevent osteoporosis
Assess QT interval prior to and during therapy to detect prolongation
Use caution in patients with history of seizures or epilepsy as treatment may increase seizure risk
Monitor mood and psychiatric status due to risk of depression and mood changes
Do not administer to pregnant or breastfeeding women due to teratogenic risk
Patients with abnormal vaginal bleeding should be evaluated for underlying pathology before treatment
Adjust pediatric dosing according to weight and clinical response for CPP treatment
Monitor blood glucose, lipid profiles, and liver function tests due to metabolic risks
Avoid abrupt discontinuation to prevent rapid reactivation of reproductive hormones
Use additional non-hormonal contraception methods as hormonal birth control may be less effective
Patients should inform healthcare providers of all concomitant medications to avoid interactions
Caution in patients with electrolyte disturbances that may predispose to cardiac arrhythmias

Warnings

Initial exacerbation of symptoms or disease flare may occur within first 2-4 weeks of therapy
Increased risk of myocardial infarction, stroke, sudden cardiac death especially in men treated for prostate cancer
QT interval prolongation which may predispose to torsades de pointes and other arrhythmias
Higher incidence of seizure events particularly in patients with predisposing risk factors
Serious psychiatric adverse events including mood disorders and behavioral changes have been reported
Risk of pseudotumor cerebri (increased intracranial pressure); symptoms require urgent evaluation
Potential for serious dermatologic reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis
Treatment may cause fetal harm and is contraindicated in pregnant women
Bone loss and increased fracture risk with prolonged use due to hypoestrogenism or hypotestosteronism
Patients with CPP may exhibit initial increased signs of puberty; monitor accordingly
Allergic reactions ranging from mild rash to anaphylaxis have been reported
Clinical monitoring essential to detect emerging adverse effects promptly
Use under careful supervision in patients with cardiovascular or neurological disorders
Discontinuation can cause return of gonadal function; counsel patients on expectations
Drug interactions may increase cardiac risk or reduce therapeutic efficacy

Contraindication

Known hypersensitivity to leuprolide acetate or any GnRH analogue
History of allergic reactions to depot formulation excipients
Pregnancy due to teratogenic potential and risk of fetal harm
Breastfeeding women as drug may pass into breast milk and affect infant
Unexplained abnormal vaginal bleeding until etiology is confirmed
Certain adult Lupron Depot formulations indicated only for use in men; not for women or children
Severe uncontrolled cardiovascular disease where hormonal therapy risk outweighs benefits
Patients with known QT prolongation or congenital long QT syndrome unless benefits outweigh risks
Absolute contraindication to GnRH analogues in known severe psychiatric instability without control
Use with caution or avoid in patients with active seizures or neurological disorders

Drug Interactions

Concomitant use with antiarrhythmic agents may increase risk of QT prolongation and arrhythmias
Drugs affecting electrolyte balance (diuretics, corticosteroids) may exacerbate cardiac risks
Bupropion and selective serotonin reuptake inhibitors (SSRIs) may increase risk of seizures when combined
Androgen deprivation therapy combined with certain chemotherapeutics or hormonal agents can alter toxicity profiles
Use with anticoagulants requires close monitoring due to potential bleeding risks
Certain antibiotics, antifungals, and antivirals that prolong QT interval may increase cardiac risk
Concurrent use with hormonal contraceptives reduces contraceptive effectiveness
Potential interaction with drugs metabolized by peptidases is minimal but data are limited
Add-back therapy agents like norethindrone acetate reduce hypoestrogenic side effects but require monitoring
Diabetes medications may require adjustment due to altered glucose metabolism during therapy
Co-administration with steroids may increase fluid retention and cardiovascular risks
Medications affecting CNS excitability could potentiate seizure risk
Drugs altering hepatic enzymes generally have minimal impact due to peptide metabolism
Patients should disclose all over-the-counter, herbal, and supplement use to avoid interactions
Monitoring is advised when initiating or discontinuing interacting drugs during Leuprolide therapy

Preparations Of The Drug

Lupron Depot 3.75 mg for 1-month administration – leuprolide acetate with acetic acid, water for injection, polysorbate 80, mannitol, purified gelatin, carboxymethylcellulose sodium
Lupron Depot 7.5 mg for 1-month administration – leuprolide acetate with purified gelatin, DL-lactic and glycolic acids copolymer, D-mannitol, carboxymethylcellulose sodium, polysorbate 80, water for injection, USP, glacial acetic acid to control pH
Lupron Depot 22.5 mg for 3-month administration – leuprolide acetate with polylactic acid, D-mannitol, carboxymethylcellulose sodium, polysorbate 80, water for injection, USP, glacial acetic acid to control pH
Lupron Depot 30 mg for 4-month administration – leuprolide acetate with polylactic acid, D-mannitol, carboxymethylcellulose sodium, polysorbate 80, water for injection, USP, glacial acetic acid USP
Lupron Depot 45 mg for 6-month administration – leuprolide acetate with polylactic acid, D-mannitol, stearic acid, carboxymethylcellulose sodium, polysorbate 80, water for injection, USP, glacial acetic acid USP
Lupron Depot-Ped 7.5 mg, 11.25 mg, 15 mg for 1-month administration – leuprolide acetate with purified gelatin, DL-lactic and glycolic acids copolymer, D-mannitol, carboxymethylcellulose sodium, polysorbate 80, water for injection, USP, glacial acetic acid USP
Lupron Depot-Ped 11.25 mg, 30 mg for 3-month administration – leuprolide acetate with polylactic acid, D-mannitol, carboxymethylcellulose sodium, polysorbate 80, water for injection, USP, glacial acetic acid USP
Lupron Depot-Ped 45 mg for 6-month administration – leuprolide acetate with polylactic acid, D-mannitol, stearic acid, carboxymethylcellulose sodium, polysorbate 80, water for injection, USP, glacial acetic acid USP